Kemin Industries expands animal vaccine capabilities with Hennessy Research acquisition

USA – Kemin Industries has announced the acquisition of Hennessy Research Associates, LLC, in a move that broadens its animal vaccine portfolio and strengthens its presence in the U.S. and global animal health markets.

The acquisition brings the Lenexa, Kansas-based research firm, situated in the U.S. “animal health corridor,” under Kemin’s umbrella, adding specialised expertise in veterinary vaccine development. 

Hennessy Research Associates, founded in 2001 by Dr. Kristina J. Hennessy, is recognised for its work in researching and developing vaccines for infectious animal diseases. 

Its team of scientists is skilled in biological manufacturing processes, in vitro test development, host animal challenge models, and USDA ELISA Reference Requalification methods.

“As Kemin continues to expand our offerings in animal vaccines, the acquisition of Hennessy Research Associates allows us to strengthen our position in the U.S. and global animal health markets with additional expertise and science-backed research that is critical to ensure the health and welfare of animals worldwide,” said Dr. Chris Nelson, President and CEO of Kemin Industries. 

“We look forward to continuing to work with Dr. Hennessy and her team of experts in serving our current and future customers.”

A legacy of innovation in animal health

Dr. Hennessy, who holds more than 30 years of experience in animal health research and is Board-Certified in Immunology by the American College of Veterinary Microbiologists, has led the company in developing patented solutions targeting infectious animal diseases. 

Under her leadership, Hennessy Research Associates evolved into a world-class R&D organisation with more than 50 tenured scientists, dedicated to focusing on research and the power of science to enhance animal health and wellness. 

“Along with my team that started and grew the company to what it is today, I’m proud to say that together we’ve built a world-class R&D organisation that truly improves animals’ lives. Knowing that Kemin shares our passion for taking care of people, animals, pets, and the planet, it was the only company that I would entrust with my team and the innovation we’ve created. This acquisition is a transformational time for our team and the future of vaccine advancements,” said Dr. Hennessy. 

Strengthening Kemin Biologics

Hennessy Research Associates will now operate within the Kemin ecosystem, specialising in veterinary biologicals as a Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), and Contract Manufacturer (CMO). 

The integration is expected to bolster Kemin Biologics, the company’s global animal vaccine business unit, which already provides high-quality, safe, and cost-effective vaccine development and manufacturing.

Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World, and follow us on our WhatsApp channel for updates.